Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

Background: Approximately 1 in 3 adults live with multiple chronic diseases. Digital health is being harnessed to improve continuity of care and management of chronic diseases. However, meaningful ...

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Ghayas C. Issa, Department of Leukemia, The University of Texas MD Anderson Cancer ...

1 School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China 2 Department of Emergency, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China Acute ...

Takeda will abandon all of its cell therapy work, retreating from research into a field it had made once made a strategic priority. The Japanese pharmaceutical giant said on Wednesday that, as part of ...

Anthony “Tony” Letai, a leukemia specialist at the Dana-Farber Cancer Institute and Harvard Medical School whose research on apoptosis and functional precision medicine helped pave the way for new ...